We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Current status and future perspectives for yttrium-90 (<sup>90</sup>Y)-ibritumomab tiuxetan in stem cell transplantation for non-Hodgkin's lymphoma.
- Authors
Gisselbrecht, C.; Bethge, W.; Duarte, R. F.; Gianni, A. M.; Glass, B.; Haioun, C.; Martinelli, G.; Nagler, A.; Pettengell, R.; Sureda, A.; Tilly, H.; Wilson, K.
- Abstract
Haematopoietic SCT is currently considered a therapeutic option mainly in relapsed or refractory non-Hodgkin's lymphoma (NHL) owing to high post-transplantation relapse rates and significant toxicity of conventional myeloablative conditioning for allogeneic SCT. Radiolabelled immunotherapy combines the benefits of monoclonal antibody targeting with therapeutic doses of radiation, and is a promising advance in the treatment of malignant lymphomas. It is now under investigation as a component of conditioning prior to SCT, with the aim of improving outcomes following SCT without increasing the toxicity of high-dose chemotherapy pre-transplant conditioning. An expert panel met at a European workshop in November 2006 to review the latest data on radiolabelled immunotherapy in the transplant setting, and its potential future directions, with a focus on 90Y-ibritumomab tiuxetan. They reviewed data on the combination of standard/high/escalating dose 90Y-ibritumomab tiuxetan with high-dose chemotherapy, and high/escalating dose 90Y-ibritumomab tiuxetan as the sole myeloablative agent, prior to autologous SCT, and also 90Y-ibritumomab tiuxetan as a component of reduced intensity conditioning prior to allogeneic SCT. The preliminary data are highly promising in terms of conditioning tolerability and patient outcomes following transplant; further phase II studies are now needed to consolidate these data and to investigate specific patient populations and NHL subtypes.Bone Marrow Transplantation (2007) 40, 1007–1017; doi:10.1038/sj.bmt.1705868; published online 8 October 2007
- Subjects
YTTRIUM isotopes; HEMATOPOIETIC stem cell transplantation; STEM cell transplantation; HODGKIN'S disease; LYMPHOMAS
- Publication
Bone Marrow Transplantation, 2007, Vol 40, Issue 11, p1007
- ISSN
0268-3369
- Publication type
Article
- DOI
10.1038/sj.bmt.1705868